Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Buildings (2016 - 2023)

Historic Buildings for China Pharma Holdings (CPHI) over the last 15 years, with Q2 2023 value amounting to $9.1 million.

  • China Pharma Holdings' Buildings fell 711.89% to $9.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $9.1 million, marking a year-over-year decrease of 711.89%. This contributed to the annual value of $9.4 million for FY2022, which is 845.56% down from last year.
  • Per China Pharma Holdings' latest filing, its Buildings stood at $9.1 million for Q2 2023, which was down 711.89% from $9.5 million recorded in Q1 2023.
  • Over the past 5 years, China Pharma Holdings' Buildings peaked at $10.3 million during Q1 2022, and registered a low of $9.1 million during Q2 2023.
  • Its 5-year average for Buildings is $9.7 million, with a median of $9.6 million in 2020.
  • Per our database at Business Quant, China Pharma Holdings' Buildings soared by 958.81% in 2021 and then plummeted by 865.38% in 2022.
  • Quarter analysis of 5 years shows China Pharma Holdings' Buildings stood at $9.4 million in 2019, then grew by 6.92% to $10.0 million in 2020, then increased by 2.34% to $10.3 million in 2021, then fell by 8.46% to $9.4 million in 2022, then fell by 3.61% to $9.1 million in 2023.
  • Its Buildings stands at $9.1 million for Q2 2023, versus $9.5 million for Q1 2023 and $9.4 million for Q4 2022.